In a significant development, U.S. District Judge M. Casey Rodgers has appointed key attorneys to lead the multidistrict litigation (MDL) against Pfizer Inc. over allegations that the company failed to adequately warn patients and doctors about the risk of brain tumors associated with the hormonal contraceptive drug Depo-Provera. Among those selected for leadership roles are attorneys from Aylstock, Witkin, Kreis & Overholtz PLC (AWKO), including Bryan Aylstock as co-lead counsel, Doug Kreis as co-chair of the science committee, and Savannah Green as a member of the Plaintiffs’ Steering Committee.
Background on Depo-Provera
Depo-Provera, also known as medroxyprogesterone acetate, is a widely used contraceptive injection administered every three months. It works by preventing ovulation, thickening cervical mucus, and thinning the uterine lining to prevent pregnancy. Additionally, it is used to manage conditions such as endometriosis and abnormal uterine bleeding. However, recent studies have linked long-term use of Depo-Provera to an increased risk of developing benign brain tumors known as meningiomas, which can cause serious health issues such as headaches, vision problems, and neurological changes.
The Multidistrict Litigation
The MDL consolidates over 70 cases alleging that Pfizer failed to adequately warn patients and healthcare providers about the potential risks of meningiomas associated with Depo-Provera. The plaintiffs argue that despite scientific evidence indicating a link between Depo-Provera and meningiomas, Pfizer did not provide sufficient warnings, thereby putting thousands of women at risk.
Congratulations to AWKO Attorneys
We extend our warmest congratulations to Bryan Aylstock, Doug Kreis, and Savannah Green for their appointments to key roles in this critical litigation. Their expertise and dedication to representing victims of defective pharmaceuticals will be invaluable in ensuring that Pfizer is held accountable for its actions.
Bryan Aylstock, as co-lead counsel, will play a pivotal role in coordinating the litigation efforts alongside lead counsel Christopher Seeger and co-lead counsel Ellen Relkin. His extensive experience in pharmaceutical litigation will be crucial in navigating the complexities of this case.
Doug Kreis, as co-chair of the science committee, will oversee the critical task of analyzing and presenting scientific evidence related to the link between Depo-Provera and meningiomas. His expertise will be essential in building a strong case against Pfizer.
Savannah Green, as a member of the Plaintiffs’ Steering Committee, will contribute to strategic decision-making and coordination of the litigation efforts. Her involvement will help ensure that the voices of all plaintiffs are represented effectively.
Your Law Firm for Multidistrict Litigation
AWKO has a long history of successfully advocating for victims of defective drugs and medical devices, having represented over 250,000 women in similar cases. The firm’s commitment to justice and its track record of securing substantial compensation for injured clients make it an ideal partner in this litigation.
As the case progresses, we look forward to seeing the impact of AWKO’s involvement in holding Pfizer accountable and ensuring that those affected by Depo-Provera receive the justice they deserve.